DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Table 5 Second line therapies in advanced PDAC

Regimens	Phase	Patients	mPFS (ms)	mOS (ms)	OS 6-ms %	DCR %	PR %	Ref
FOLFIRINOX	Ret	22	5.4	8.5	n.a.	63	19	[32] 2011
FOLFIRINOX	Ret	18	2.8	8.4	44.4	55.6	27.8	[33] 2013
Nab-Paclitaxel	II	19	1.7	7.3	58	37	5	[31] 2012
FOLFIRI	II	50	3.2	5.0	32	36	8	[18] 2012
Capecitabine/Docetaxel	II	43	3.7	5.3	n.a.	73	14	[34] 2014
mFOLFOX	II	30	1.5	3.7	30	17	7	[28] 2009
FOLFIRI		31	2.1	4.2	27	23	0	[28] 2009
OFF	III	23	n.a.	4.8	n.a.	n.a.	n.a.	[8] 2011
BSC	III	23	n.a.	2.3	n.a.	n.a.	n.a.	[8] 2011
OFF	III	76	2.9	5.9	n.a.	n.a.	n.a.	[9] 2014
FF	III	84	2.0	3.3	n.a.	n.a.	n.a.	[9] 2014
Xelox	II	39	2.5	5.8	44	28.6	2.6	[35] 2008
Docetaxel	Ret	17	2	4	n.a.	35	6	[15] 2010
Nal-Iri	II	40	2.4	5.2	42.5	50	7.5	[27] 2013
Nal-Iri/5-FU/LV	III	417	3.1	6.1	n.a.	n.a.	n.a.	[10] 2014
5-FU/LV	III	417	1.5	4.2	n.a.	n.a.	n.a.	[10] 2014
GEMOX	II	33	4.2	6	n.a.	61.3	22.6	[36] 2006
Vatalanib	II	67	2	n.a.	29	31	3	[37] 2014
DocOx	II	44	1.8	10.1	56.8	48	15.9

mPFS median progression free survival time, mOS median overall survival time, Ref reference, Ret Retrospective, ms months, DCR disease control rate, PR partial remission, ms months, OFF oxaliplatin, folinic acid, fluorouracil, LV leucovorine, 5-FU 5-fluorouracil, Nab-Paclitaxel nanoalbumine bound pacitaxel, Nal-Iri nanoliposomal irinotecan, FOLFIRI fluorouracil, leucovorine, irinotecan, FOLFOX fluorouracil, leucovorine, oxaliplatin, FOLFIRINOX fluorouracil, leucovorine, irinotecan, oxaliplatin, DocOx docetaxel oxaliplatin, n.a. not applicable, Ref Reference and publication date

ISSN: 1471-2407